Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sucrose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.70 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL2383084 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL6241474 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL5972240 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL5012470 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL7861331 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL1001768 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL6638490 | 0.96 | CDK1 (0.68) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL9800251 | 0.96 | CDK1 (0.68) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL8795457 | 0.94 | CDK1 (0.68) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL3506279 | 0.94 | CDK1 (0.68) | CDK1CCNB1CA2CA9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5023072-A | Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract | UNIVERSITY OF NEW MEXICO (US) | 1991-06-11 | — | — | US | claimed |
| US-20100055040-A1 | Optical Imaging Contrast Agents | MALLINCKRODT INC. | 2010-03-04 | — | — | US | disclosed |
| CN-101203248-A | Optical imaging contrast agents | MALLINCKRODT INC (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1901781-A2 | OPTICAL IMAGING CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007002332-A2 | OPTICAL IMAGING CONTRAST AGENTS | MALLINCKRODT INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-1994000476-A1 | USE OF WATER-SOLUBLE SUCROSES FOR THE TREATMENT AND/OR PREVENTION OF LESION OR INFLAMMATION IN THE DIGESTIVE TRACT | BUKH MEDITEC A/S (DK) | 1994-01-06 | — | — | WO | disclosed |
| US-5023072-A | Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract | UNIVERSITY OF NEW MEXICO (US) | 1991-06-11 | — | — | US | disclosed |
| US-4851209-A | Diagnostic procedures using radio labeled sucralfate and derivatives or precursors thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-07-25 | — | — | US | disclosed |
| US-4581221-A | TECHNETIUM LABELLED CARRIER REACTED WITH AN ULCER SPECIFIC OLIGOSACCHARIDE SULFATE | MEDI NUCLEAR CORPORATION, INC. (US) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055040-A1 | Optical Imaging Contrast Agents | SI, FABP2, ALPI | CDK1 3653/4885CCNB1 4043/4885CA2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.